ID   PC-3/MA2
AC   CVCL_6E87
SY   PC-3 MA2
DR   cancercelllines; CVCL_6E87
DR   Wikidata; Q54938451
RX   PubMed=447482;
RX   PubMed=7459854;
RX   PubMed=10754530;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9555 ! PC-3M
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 05-10-23; Version: 11
//
RX   PubMed=447482;
RA   Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W.;
RT   "Establishment and characterization of a human prostatic carcinoma
RT   cell line (PC-3).";
RL   Invest. Urol. 17:16-23(1979).
//
RX   PubMed=7459854;
RA   Kirk D., Szalay M.F., Kaighn M.E.;
RT   "Modulation of growth of a human prostatic cancer cell line (PC-3) in
RT   agar culture by normal human lung fibroblasts.";
RL   Cancer Res. 41:1100-1103(1981).
//
RX   PubMed=10754530; DOI=10.1002/(SICI)1097-0045(20000501)43:2<144::AID-PROS9>3.0.CO;2-H;
RA   Suzuki Y., Kondo Y., Himeno S., Nemoto K., Akimoto M., Imura N.;
RT   "Role of antioxidant systems in human androgen-independent prostate
RT   cancer cells.";
RL   Prostate 43:144-149(2000).
//